Hazard Information | Back Directory | [Uses]
Ginisortamab (UCB6114) is a fully human IgG4P antiGremlin-1 monoclonal antibody, with mean IC50 values of 8.2 nM and 9 nM against human and mouse gremlin-1, respectivly. Ginisortamab inhibits gremlin-1 antagonism of BMP signaling pathways. Ginisortamab has the potential for the research of gastrointestinal (GI) tumors[1][2][3]. | [in vivo]
Ginisortamab binds to gremlin-1 and has antitumor activity in several mouse models, including GI cancers[3].
| [References]
[1] Debashis Sarker, et al. A multi-modular phase I/II study of UCB6114, a first-in-class, fully human IgG4P anti-Gremlin-1 monoclonal antibody, as monotherapy and in combination with mFOLFOX6 or trifluridine/tipiracil, for patients with advanced gastrointestinal (GI) tumors. Meeting Abstract, 2022 ASCO Gastrointestinal Cancers Symposium. [2] Davies GCG, et al. Discovery of ginisortamab, a potent and novel anti-gremlin-1 antibody in clinical development for the treatment of cancer. MAbs. 2023 Jan-Dec;15(1):2289681. DOI:10.1080/19420862.2023.2289681 [3] Debashis Sarker, et al. Abstract CT094: Phase I dose-escalation study evaluating the safety and tolerability of ginisortamab (UCB6114), a first-in-class anti-gremlin-1 monoclonal antibody (mAb), as monotherapy in advanced solid tumors. Cancer Res (2023) 83 (8_Supplement): CT094 . |
|
Company Name: |
Biolab Reagents
|
Tel: |
18108604356 18108604356 |
Website: |
www.biolabreagent.com/ |
Company Name: |
Cell Sciences
|
Tel: |
9785721070 |
Website: |
www.cellsciences.com |
|